Beta Bionics officer proposes $12.6K share sale

The proposed shares are listed as acquired through stock options for cash, alongside a Rule 10b5-1 plan adoption date of July 31, 2026.

Available on EDGAR 11/09/2026 - 04:52 PM EST Accepted by SEC EDGAR 11/09/2026 - 04:52 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Beta Bionics, Inc. (BBNX) officer Stephen Feider reported a proposed sale of 744 common shares, with an aggregate market value of $12,649 and an approximate sale date of November 9, 2026. The shares are listed as acquired from the issuer through stock options for cash on November 9, 2026; the reported Rule 10b5-1 plan adoption date is July 31, 2026. Beta Bionics had 54,367,067 common shares outstanding. Feider's recent sales listed were 382 shares for gross proceeds of $6,508 on November 5, 2026, and 6,675 shares for gross proceeds of $129,595.13 on September 2, 2026.

Key Figures

Proposed common shares for sale: 744 shares Aggregate market value: $12,649 Common shares outstanding: 54,367,067 shares +5 more

8 metrics

Proposed common shares for sale 744 shares Approximate sale date November 9, 2026

Aggregate market value $12,649 Proposed sale of 744 common shares

Common shares outstanding 54,367,067 shares Beta Bionics

Rule 10b5-1 plan adoption date July 31, 2026 Date listed for the proposed sale

Prior common shares sold 382 shares Sale dated November 5, 2026

Gross proceeds $6,508 Sale dated November 5, 2026

Prior common shares sold 6,675 shares Sale dated September 2, 2026

Gross proceeds $129,595.13 Sale dated September 2, 2026

Key Terms

Rule 10b5-1, Stock Options, Aggregate Market Value, Gross Proceeds

4 terms

Rule 10b5-1 regulatory

"Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Stock Options financial

"Nature of Acquisition Transaction: Stock Options"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

Aggregate Market Value financial

"Aggregate Market Value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Gross Proceeds financial

"Gross Proceeds"

The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BBNX shares does Stephen Feider propose to sell?

Stephen Feider's reported proposed sale is 744 common shares, with an aggregate market value of $12,649. The approximate sale date is November 9, 2026.

What recent BBNX share sales are listed for Stephen Feider?

The sales listed are 382 common shares for gross proceeds of $6,508 on November 5, 2026, and 6,675 common shares for gross proceeds of $129,595.13 on September 2, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002048588
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Beta Bionics, Inc.
SEC File Number	001-42491
Address of Issuer	11 Hughes Irvine CALIFORNIA 92618
Phone	9494277785
Name of Person for Whose Account the Securities are To Be Sold	Stephen Feider
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 5951 La Sendita, Bldg A. Rancho Santa Fe CA 92067	744	12649	54367067	11/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/09/2026	Stock Options	Issuer			744	11/09/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Stephen Feider 11 Hughes Irvine CA 92618	Common	11/05/2026	382	6508
Stephen Feider 11 Hughes Irvine CA 92618	Common	09/02/2026	6675	129595.13

144: Remarks and Signature

Remarks
Date of Notice	11/09/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	07/31/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Stephen Feider
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)